Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013469 | 0.86 | ADRB2 (0.36) | ADRB2ADRB1HTR2AHTR2CSLC6A4 | |
| SCHEMBL2010994 | 0.85 | ALDH1A1 (0.31) | HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL14850524 | 0.81 | ADRB2 (0.42) | ADRB2ADRB1 | |
| SCHEMBL824894 | 0.77 | ALDH1A1 (0.41) | DAO | |
| SCHEMBL2013081 | 0.74 | FAAH (0.42) | — | |
| SCHEMBL5028917 | 0.73 | TSHR (0.48) | HTR2AHTR2CSLC6A4HTR2BDAO | |
| SCHEMBL2008810 | 0.68 | ADRB2 (0.39) | ADRB2ADRB1HTR2AHTR2CSLC6A4 | |
| SCHEMBL10232106 | 0.68 | LTA4H (0.42) | ADRB2ADRB1 | |
| SCHEMBL2007253 | 0.68 | ADRB2 (0.34) | ADRB2ADRB1 | |
| SCHEMBL2011284 | 0.68 | ALDH1A1 (0.38) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420669-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor | LABORATORIES ALMIRALL, S.A. (ES) | 2013-04-16 | — | — | US | disclosed |
| US-8242177-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2012-08-14 | — | — | US | disclosed |
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-05-10 | — | — | US | disclosed |
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | US | disclosed |
| EP-1885684-B9 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-20110251165-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. | 2011-10-13 | — | — | US | disclosed |
| US-20110251166-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | PUIG DURAN CARLOS | 2011-10-13 | — | — | US | disclosed |
| EP-1885684-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-07-13 | — | — | EP | disclosed |
| US-7964615-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| EP-2263998-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor | Almirall S.A. (ES) | 2010-12-22 | — | — | EP | disclosed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| EP-1885684-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006122788-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251166-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885HTR2A 180/4885 |
| US-20110251165-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB3 | ADRB2 1/4885ADRB1 4/4885HTR2A 173/4885 |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885HTR2A 166/4885 |
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885HTR2A 95/4885 |
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885HTR2A 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.